EdwinDeJesusMDFACP, FIDSA

Infectious Disease • Orlando, FL

HIV/AIDS Medicine, STD Medicine

Medical Director - Orlando Immunology Center and Assistant Professor - UCF College of Medicine

Join to view full profile

Dr. DeJesus is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. DeJesus' full profile

Already have an account?

Office
1707 N Mills Ave
Orlando, FL 32803
Phone+1 407-647-3960

Fax+1 407-413-5775

Education & Training

Drexel University College of Medicine/Hahnemann University HospitalFellowship, Infectious Disease, 1991 - 1993
Drexel University College of Medicine/Hahnemann University HospitalResidency, Internal Medicine, 1988 - 1991
University of Puerto Rico School of MedicineClass of 1988

Certifications & Licensure

FL State Medical License 1993 - 2026
PA State Medical License 1990 - 1994

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Centricity Practice Solution EMR, GE Healthcare, 2014

Clinical Trials

Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation Start of enrollment: 2006 Mar 31
Completed
Phase 1, Phase 2
Evolution of L74V or K65R Mutations in VIremic Subjects on Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) (EVITA) Start of enrollment: 2006 Apr 01
Completed
Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A Start of enrollment: 2006 Sep 01
Completed
Phase 2
HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network Start of enrollment: 2011 Nov 01
Completed
Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV Start of enrollment: 2015 Aug 01
Completed
Phase 3
Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1 Start of enrollment: 2016 Mar 01
Completed
Phase 3
A Clinical Trial of STP0404 in Treatment-Naïve Adults With HIV-1 Infection Start of enrollment: 2023 May 23
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

700 citations
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
Joel E. Gallant, Edwin DeJesus, Jose R. Arribas, Anton Pozniak, Brian Gazzard
The New England Journal of Medicine. 2006-01-19
608 citations
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribav...
Eric Lawitz, Mark S. Sulkowski, Reem Ghalib, Maribel Rodriguez-Torres, Zobair M. Younossi
Lancet. 2014-11-15
21 citations
Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVT...
Youyi Fong, Xiaoying Shen, Vicki C Ashley, Aaron Deal, Kelly E. Seaton
The Journal of Infectious Diseases. 2018-03-28

Journal Articles

Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection
Michael Kozal, Edwin Dejesus, Cyril Llamoso, The New England Journal of Medicine

Press Mentions

Treatment-Related Early Discontinuations and Adverse Events Among Newly Diagnosed People Living with HIV Initiating Integrase Inhibitors in a Real-World SettingFebruary 1st, 2023
Orlando Trial for New Types of COVID-19 Monoclonal Antibody Treatment Seeks ParticipantsDecember 15th, 2021
'Elite Neutralizing' Antibody Demonstrates Long-Term Viral Suppression in Persons Living with HIV in Phase 1 TrialOctober 14th, 2021
Join now to see all